Pharmacovigilance in public health is a critical component of ensuring the safety and effectiveness of pharmaceutical products once they are on the market. It involves the systematic monitoring, assessment, and prevention of adverse effects or any other drug-related problems. Public health pharmacovigilance activities aim to protect the population from potential harm associated with the use of medications. Robust pharmacovigilance systems involve the collection and analysis of data from various sources, including healthcare professionals, patients, and regulatory agencies. Early detection of adverse drug reactions allows for timely intervention, minimizing risks and ensuring the continued safe use of medications. Pharmacovigilance contributes to evidence-based decision-making in healthcare by providing information on the risk-benefit profile of drugs. It plays a crucial role in post-marketing surveillance, detecting rare or long-term side effects that may not have been evident during pre-market clinical trials. Collaboration between regulatory authorities, healthcare providers, and the pharmaceutical industry is essential for the success of pharmacovigilance programs. Public awareness campaigns educate healthcare professionals and the public about the importance of reporting adverse drug reactions, fostering a culture of transparency and accountability. As new drugs are introduced and treatment patterns evolve, pharmacovigilance remains indispensable in maintaining the safety and integrity of public health pharmacotherapy.
Speaker lineup for this track will be announced soon.
Browse all speakers →Background: Renal anaemia remains a pervasive challenge among individuals with chronic kidney disease (CKD), often being underdiagnosed and inadequately treated. The advent of hypoxia-inducible…
Introduction: Pharmacovigilance plays a vital role in public health, focusing on the detection, evaluation, and prevention of adverse drug reactions (ADRs). Despite its importance, the high…
Background: Adverse drug reaction (ADR) reporting plays a critical role in ensuring patient safety and improving pharmacovigilance systems. 1 National Pharmacovigilance awareness Week aims to enhance…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Pharmacovigilance in Public Health work, reviewed by the scientific committee.
Meet public health researchers, educators, and policy leaders from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Pharmacovigilance in Public Health research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Pharmacovigilance in Public Health track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Pharmacovigilance in Public Health. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Pharmacovigilance in Public Health are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. IPHC 2027 is a hybrid conference — attend the Pharmacovigilance in Public Health track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
